Hepatitis E virus RNA in Australian blood donations

Transfusion

Volumn 56, Issue 12, 2016, Pages 3086-3093

  Shrestha, Ashish C ^a   Flower, Robert L P ^a   Seed, Clive R ^b   Keller, Anthony J ^b   Harley, Robert ^b   Chan, Hiu Tat ^b   Hoad, Veronica ^b   Warrilow, David ^c   Northill, Judith ^c   Holmberg, Jerry A ^d   Faddy, Helen M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Medication Services   (Australia)

^c Virology Queensl and Health Forensic and Scientific Services   (Australia)

^d Grifols Diagnostic Solutions Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ARTICLE; AUSTRALIAN; BLOOD DONOR; CONTROLLED STUDY; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; PHYLOGENY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIREMIA; VIRUS LOAD; ADVERSE EFFECTS; AUSTRALIA; BLOOD; BLOOD SAFETY; BLOOD TRANSFUSION; GENETICS; POLYMERASE CHAIN REACTION; SEROEPIDEMIOLOGY; TRANSMISSION;

AUSTRALIA; BLOOD DONORS; BLOOD SAFETY; BLOOD TRANSFUSION; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; PHYLOGENY; POLYMERASE CHAIN REACTION; RNA, VIRAL; SEROEPIDEMIOLOGIC STUDIES; VIRAL LOAD;

EID: 85003747688     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13799     Document Type: Article

References (59)

1. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet 2012;379:2477–88.
2. Scobie L, Dalton HR. Hepatitis E: source and route of infection, clinical manifestations and new developments. J Viral Hepat 2013;20:1–11.
3. Dalton HR, Bendall R, Ijaz S, et al. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008;8:698–709.
4. Hepatitis E: epidemiology and disease burden [Internet]. Geneva: World Health Organization; 2014 [cited 2015 Dec 3]. Available from: http://www.who.int/immunization/sage/meetings/2014/october/1_HEV_burden_paper_final_03_Oct_14_yellow_book.pdf.
5. Boxall E, Herborn A, Kochethu G, et al. Transfusion-transmitted hepatitis E in a ‘nonhyperendemic’ country. Transfus Med 2006;16:79–83.
6. Matsui T, Kang JH, Matsubayashi K, et al. A rare case of transfusion-transmitted hepatitis E from the blood of a donor infected with the hepatitis E virus genotype 3 indigenous to Japan: viral dynamics from onset to recovery. Hepatol Res 2015;45:698–704.
7. Colson P, Coze C, Gallian P, et al. Transfusion-associated hepatitis E, France. Emerg Infect Dis 2007;13:648–9.
8. Kamar N, Dalton HR, Abravanel F, et al. Hepatitis E virus infection. Clin Microbiol Rev 2014;27:116–38.
9. Hogema BM, Molier M, Sjerps M, et al. Incidence and duration of hepatitis E virus infection in Dutch blood donors. Transfusion 2016;56:722–8.
10. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008;358:811–7.
11. Schlosser B, Stein A, Neuhaus R, et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. J Hepatol 2012;56:500–2.
12. Tamura A, Shimizu YK, Tanaka T, et al. Persistent infection of hepatitis E virus transmitted by blood transfusion in a patient with T-cell lymphoma. Hepatol Res 2007;37:113–20.
13. Kamar N, Izopet J, Dalton HR. Chronic hepatitis E virus infection and treatment. J Clin Exp Hepatol 2013;3:134–40.
14. Abravanel F, Lhomme S, Chapuy-Regaud S, et al. Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections. J Infect Dis 2014;209:1900–6.
15. Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 2014;384:1766–73.
16. Ikeda H, Matsubayashi K, Sakata H, et al. Prevalence of hepatitis E virus infection among Japanese blood donors. ISBT Sci Ser 2009;4:299–301.
17. Vollmer T, Diekmann J, Johne R, et al. Novel approach for detection of hepatitis E virus infection in German blood donors. J Clin Microbiol 2012;50:2708–13.
18. Shrestha AC, Faddy HM, Flower RL, et al. Hepatitis E virus: do locally acquired infections in Australia necessitate laboratory testing in acute hepatitis patients with no overseas travel history? Pathology 2015;47:97–100.
19. Cleland A, Smith L, Crossan C, et al. Hepatitis E virus in Scottish blood donors. Vox Sang 2013;105:283–9.
20. Sauleda S, Ong E, Bes M, et al. Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain). Transfusion 2015;55:972–9.
21. Fischer C, Hofmann M, Danzer M, et al. Seroprevalence and incidence of hepatitis E in blood donors in Upper Austria. PLoS One 2015;10:e0119576.
22. Ren F, Zhao C, Wang L, et al. Hepatitis E virus seroprevalence and molecular study among blood donors in China. Transfusion 2014;54:910–7.
23. Huzly D, Umhau M, Bettinger D, et al. Transfusion-transmitted hepatitis E in Germany, 2013. Euro Surveill 2014;19:20812.
24. Implementation of the supply of hepatitis E virus (HEV) tested components [Internet]. London: NHS Blood and Transplant; 2015 [cited 2016 Apr 18]. Available from: http://www.nhsbt.nhs.uk/download/board_papers/nov15/15_86.pdf.
25. IBTS first national transfusion service to roll out non-invasive haemoglobin check for blood donors [Internet]. Dublin: Irish Blood Transfusion Service; 2015 [cited 2016 Apr 18]. Available from: https://www.giveblood.ie/About_Us/Newsroom/Press_Releases/2015/IBTS-first-national-transfusion-service-to-roll-out-non-invasive-haemoglobin-check-for-blood-donors.html.
26. France—more stringent blood donor testing requirements 2015 Mapping exercise [Internet]. Brussels: The European Commission; 2015 [cited 2016 Apr 22] Available from: http://ec.europa.eu/health/blood_tissues_organs/docs/msr_fr_en.pdf.
27. Hauser L, Roque-Afonso AM, Beylouné A, et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood 2014;123:796–7.
28. Shrestha AC, Flower RL, Seed CR, et al. Virus infections in travellers: a threat in Australia? Vox Sang 2015;109:67–8.
29. Yapa CM, Furlong C, Rosewell A, et al. First reported outbreak of locally acquired hepatitis E virus infection in Australia. Med J Aust 2016;204:274.
30. Chandler JD, Riddell MA, Li F, et al. Serological evidence for swine hepatitis E virus infection in Australian pig herds. Vet Microbiol 1999;68:95–105.
31. Shrestha AC, Seed CR, Flower RL, et al. Hepatitis E virus and implications for blood supply safety, Australia. Emerg Infect Dis 2014;20:1940–2.
32. Speers DJ, Ma MX, Faddy HM, et al. Domestically acquired hepatitis E successfully treated with ribavirin in an Australian liver transplant recipient. Med J Aust 2015;202:209–11.
33. Guidelines for the selection of blood donors: Australian Red Cross Blood Service. ARCBS-DAP-L2-001 | Version: 014. Melbourne: Australian Red Cross Blood Service; 2013.
34. Matsubayashi K, Sakata H, Iida J, et al. HEV RNA screening in blood donors in Hokkaido, Japan. Blood Transfus 2013;s45.
35. Abravanel F, Chapuy-Regaud S, Lhomme S, et al. Performance of two commercial assays for detecting hepatitis E virus RNA in acute or chronic infections. J Clin Microbiol 2013;51:1913–6.
36. Vollmer T, Knabbe C, Dreier J. Comparison of real-time PCR and antigen assays for detection of hepatitis E virus in blood donors. J Clin Microbiol 2014;52:2150.
37. Zhang F, Li X, Li Z, et al. Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E. J Med Virol 2006;78:1441–8.
38. Plus ELISA [Internet]. Beijing: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.; 2014 [cited 2014 Oct 22]. Available from: http://www.ystwt.cn/IFU/HEV/HEV-Ag%20Plus%20CE.pdf.
39. Schnegg A, Bürgisser P, André C, et al. An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. PLoS One 2013;8:e62980.
40. Bendall R, Ellis V, Ijaz S, et al. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol 2010;82:799–805.
41. Huang F, Yu W, Hua X, et al. Seroepidemiology and molecular characterization of hepatitis E Virus in Macaca mulatta from a village in Yunnan, China, where infection with this virus is endemic. Hepat Mon 2011;11:745.
42. HEV-IgG ELISAWantai [Internet]. Beijing: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.; 2014 [cited 2014 Oct 22]. Available from: http://www.ystwt.cn/IFU/HEV/HEV-IgG_CE.pdf.
43. HEV-IgM ELISAWantai [Internet]. Beijing: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.; 2014 [cited 2014 Oct 22] Available from: http://www.ystwt.cn/IFU/HEV/HEV-IgM_CE.pdf.
44. La Rosa G, Fratini M, Muscillo M, et al. Molecular characterisation of human hepatitis E virus from Italy: comparative analysis of five reverse transcription-PCR assays. Virol J 2014;11:72.
45. Tamura K, Peterson D, Peterson N, et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011;28:2731–9.
46. Mood AM, Graybill FA, Boes DC. Introduction to the theory of statistics. Noida, India: McGraw Hill; 2001.
47. Petrik J, Lozano M, Seed CR, et al. Hepatitis E. Vox Sang 2015;1–38.
48. Zaaijer HL. No artifact, hepatitis E is emerging. Hepatology 2015;62:654.
49. Stramer SL, Moritz ED, Foster GA, et al. Hepatitis E virus: seroprevalence and frequency of viral RNA detection among US blood donors. Transfusion 2016;56:481–8.
50. Guo QS, Yan Q, Xiong JH, et al. Prevalence of hepatitis E virus in Chinese blood donors. J Clin Microbiol 2010;48:317–8.
51. Faber MS, Wenzel JJ, Jilg W, et al. Hepatitis E virus seroprevalence among adults, Germany. Emerg Infect Dis 2012;18:1654–7.
52. Slot E, Hogema BM, Riezebos-Brilman A, et al. Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. Euro Surveill 2013;18:20550.
53. Aggarwal R. The global prevalence of hepatitis E virus infection and susceptibility: a systematic review [Internet]. Geneva: World Health Organization; 2010 [cited 2014 Jul 28]. Available from: http://whqlibdoc.who.int/hq/2010/WHO_IVB_10.14_eng.pdf.
54. Australia's notifiable disease status, 2012: annual report of the National Notifiable Diseases Surveillance System. Canberra: Department of Health, Australian Government; 2012 [cited 2014 Jul 8]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3901-pdf-cnt.htm/FILE/cdi3901g.pdf.
55. Mansuy JM, Gallian P, Dimeglio C, et al. A nationwide survey of hepatitis E viral infection in French blood donors. Hepatology 2016;63:1145–54.
56. Hogema BM, Molier M, Slot E, et al. Past and present of hepatitis E in the Netherlands. Transfusion 2014;54:3092–6.
57. Ijaz S, Said B, Boxall E, et al. Indigenous hepatitis E in England and Wales from 2003 to 2012: evidence of an emerging novel phylotype of viruses. J Infect Dis 2014;209:1212.
58. Baylis SA, Gärtner T, Nick S, et al. Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. Vox Sang 2012;103:89–90.
59. Perez-Gracia MT, Suay B, Mateos-Lindemann ML. Hepatitis E: an emerging disease. Infect Genet Evol 2014;22:40–59.